Corepharma Likely Will Receive Exclusivity For Two Carbatrol Generic Doses
This article was originally published in The Pink Sheet Daily
Executive Summary
Shire lawsuit triggers 30-month stay of approval of Corepharma’s ANDA for the epilepsy drug.